HealthDay News — Hepatitis B virus (HBV) screening is recommended for patients undergoing chemotherapy, immunosuppressive therapy, or transplantation, according to research published in Hepatology.
HBV reactivation, which may occur with a variety of immunosuppressive therapies in benign or malignant disease, may be severe and potentially fatal, said Adrian M. Di Bisceglie, MD, of the St. Louis University School of Medicine, and colleagues.
All patients undergoing immunotherapy, hematopoietic stem cell transplantation, or solid organ transplantation should undergo HBV screening by testing for hepatitis B surface antigen (HBsAg) and antibody to hepatitis B core antigen in serum.
To prevent reactivation, appropriate antiviral therapy should be given to patients who are found to be HBsAg positive. Due to the risks associated with a form of HBV reactivation, known as reverse seroconversion, even those who have recovered from HBV will benefit from antiviral therapy in specific circumstances.
“There is good evidence to support routine screening of all patients for hepatitis B prior to undergoing chemotherapy or immunosuppressive treatment,” wrote the authors.
“Use of prompt antiviral treatment appears to diminish the risk of severe or fatal reactivation of hepatitis B.”